**Persistent neuropathological effects 14 years following amyloid-β immunisation in Alzheimer’s disease**

James AR Nicoll1,2, George R Buckland1, Charlotte H Harrison1, Anton Page3, Scott Harris4, Seth Love5, James W Neal6, Clive Holmes1,7, Delphine Boche1

1Clinical Neurosciences, Clinical & Experimental Sciences, University of Southampton, Southampton, UK

2Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

3Biomedical Imaging Unit, Faculty of Medicine, University of Southampton, Southampton, UK

4Public Health Sciences and Medical Statistics, Faculty of Medicine, University of Southampton, UK

5Department of Neuropathology, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom

6Department of Cellular Pathology, University Hospital of Wales, Cardiff University, Cardiff, UK

7Memory Assessment and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton, UK

In memory of Dr Dale Schenk, pioneer of immunotherapy for Alzheimer’s disease, without whom this study would not have been possible.

**Corresponding author**

Prof Delphine Boche, Clinical Neurosciences, Clinical & Experimental Sciences, University of Southampton, Southampton SO16 6YD, UK

Tel: +44 2381 206 107 Email: d.boche@soton.ac.uk

Short running title: Amyloid-β immunisation in Alzheimer’s disease**Abstract**

We performed a 15-year *post-mortem* neuropathological follow-up of patients in the first trial of amyloid-β immunotherapy for Alzheimer’s disease. Twenty-two participants of a clinical trial of active amyloid-β42 immunisation (AN1792, Elan Pharmaceuticals) or placebo were studied. Comprehensive *post-mortem* neuropathological assessments were performed from 4 months to 15 years after the trial. We analysed the relationships between the topographical distribution of amyloid-β removal from the cerebral cortex and tau pathology, cerebrovascular territories, plasma anti-AN1792 antibody titres and late cognitive status.

Seventeen of 22 (77%) participants had Alzheimer’s neuropathological change, whereas five of 22 (23%) had alternative causes for dementia (progressive supranuclear palsy = 1, Lewy body disease = 1, vascular brain injury = 1, and frontotemporal lobar degeneration = 2). Nineteen of the 22 participants had received the active agent, three the placebo. Fourteen of 16 (88%) Alzheimer’s disease patients receiving the active agent had evidence of plaque removal (very extensive removal = 5, intermediate = 4, very limited = 5, no removal = 2). Of particular note, two Alzheimer’s patients who died 14 years after immunisation had only very sparse or no detectable plaques in all regions examined. There was a significant inverse correlation between post-vaccination peripheral blood anti-AN1792 antibody titres and *post-mortem* plaque scores (*=*-0.664, *p*=0.005). Cortical foci cleared of plaques contained less tau than did cortex with remaining plaques, but the overall distribution of tangles was extensive (Braak V/VI).

In conclusion, Alzheimer’s patients actively immunised against amyloid-β can remain virtually plaque–free for 14 years. The extent of plaque removal is related to the immune response. This long duration of efficacy is important in support of active immunisation protocols as therapy for, or potentially prevention of, neurodegeneration-associated protein accumulations. Inclusion of patients without Alzheimer’s disease in Alzheimer’s therapy trials is a problem for assessing the efficacy of treatment. Despite modification of Alzheimer’s pathology, most patients had progressed to severe dementia, notably including the five with very extensive plaque removal, possibly due to continued tau propagation. Neuropathology follow-up of patients in therapeutic trials provides valuable information on the causes of dementia and effects of treatment.

Keywords: Alzheimer’s disease, dementia, immunotherapy, neuropathology, amyloid-β

**Abbreviations**

A Amyloid-

*APOE* Apolipoprotein E

ptau phosphorylated tau

**Introduction**

The concept of immunisation against amyloid-β (Aβ) for the treatment of Alzheimer’s disease has been under investigation for nearly 20 years. The amyloid cascade hypothesis states that Aβ abnormalities play a key initiating role in Alzheimer’s disease pathophysiology, making Aβ a target for the treatment or prevention of the disease (Selkoe and Hardy, 2016). In a mouse model, Aβ immunisation early in life prevented Aβ plaque formation (Schenk *et al.*, 1999), whereas in aged mice it reduced the plaque burden (Schenk *et al.*, 1999) and protected against neurological dysfunction (Morgan *et al.*, 2000).

The same experimental approach, using multiple peripheral inoculations of full-length Aβ42 peptide with adjuvant, designated AN1792 (Elan Pharmaceuticals), resulted in a human clinical trial which began in 2000 (Bayer *et al.*, 2005). The first *post-mortem* neuropathological study of a patient receiving Aβ immunisation (Nicoll *et al.*, 2003) suggested profound changes in Alzheimer’s pathology, prompting us to instigate a systematic clinical and neuropathological follow-up of participants in the AN1792 trial. The main aims of that initial clinical trial were to evaluate the safety and immunogenicity of AN1792 (Bayer *et al.*, 2005). A total of 80 patients was recruited with a clinical diagnosis of mild to moderate Alzheimer’s disease. Sixty-four patients received the active agent with variable doses of AN1792 (50 or 225µg) and variable doses of adjuvant (QS-21, 50 or 100µg) and 16 patients received adjuvant alone. Patients received four injections over a 24-week period and some received up to four further injections of a modified formulation up to week 72 of the study. During the period of the first four injections, 23.4% of patients developed detectable circulating anti-AN1792 antibodies, rising to 58.8% of patients after additional injections. Although the trial was not designed to assess efficacy, one out of four clinical assessments employed (Disability Assessment for Dementia) showed significantly less decline in the treated group than the controls after 84 weeks (Bayer *et al.*, 2005). Our clinical follow-up at six years showed no evidence of improved survival or delayed development of severe dementia in treated patients compared with those receiving the placebo (Holmes *et al.*, 2008). Even very extensive removal of Aβ plaques from the brain seemed insufficient to halt cognitive decline, although this conclusion was based on only two patients (Holmes *et al.*, 2008) and was thought to require confirmation in a larger sample.

Consequently, here we report a 15-year *post-mortem* neuropathology follow-up study of 22 of the 80 participants in the first clinical trial of Aβ immunotherapy (Bayer *et al.*, 2005). Our aims were first, to perform neuropathological assessment to determine the accuracy of the clinical diagnosis of Alzheimer’s disease in the setting of this trial; second, to assess the duration of effects of immunotherapy on neuropathology and dementia status, many years after treatment; third, to explore factors that might contribute to the variability of responses, in particular the relationship of the extent of Aβ removal to circulating anti-AN1792 antibody titres and to cerebrovascular territories; and last, to analyse the effects of Aβ removal on tau pathology in this unique cohort of immunised Alzheimer’s cases.

**Patients and Methods**

**Subjects, ethics and consent**

Ethical approval was obtained to follow up participants in the trial and seek their consent for *post-mortem* brain donation (Southampton and South West Hampshire Local Research Ethics Committees, Reference No. LRC 075/03/w). Twenty-two participants and their carers consented and brain donations were complete by the end of 2015. Trial data were made available by Elan Pharmaceuticals and included: duration of dementia at trial entry, AN1792 dose, AN1792 number of doses, assays of peripheral blood anti-AN1792 antibodies, *APOE* genotypes and date of first immunisation dose (Table 1). Subsequent assessment of dementia at a late stage prior to death was based on the last known assessment of activities of daily living scores and cognitive scores. Causes of death were obtained from death certificates.

**Neuropathological diagnoses**

All assessments were performed blind to the treatment status of the cases. Brains were examined and sampled for histology by standard methods after fixation in formalin. From each case, additional large coronal slices of cerebral hemisphere were processed. Paraffin sections were stained with haematoxylin and eosin, and immunohistochemistry was performed with antibodies including pan-Aβ (clone 6F/3D, Novocastra, UK), tau (phosphorylated and non-phosphorylated tau, clone Tau-2, Sigma, UK), phosphorylated (p)tau (clone AT8 Autogenbioclear, UK) and CD3 (pan-T lymphocytes, Abcam). Additionally, antibodies to α-synuclein (clone KM51, Novocastra), ubiquitin (clone ab7780, Abcam) and TDP43 (clone 10782-2-AP, Proteintech) were used when required for diagnosis. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathological assessment of Alzheimer’s disease were employed (Hyman *et al.*, 2012; Montine *et al.*, 2012).

**Aβ assessments**

*Method 1.* Sections immunolabelled for Aβ from all cerebral cortical regions sampled, including frontal, temporal, parietal and occipital lobes, representing both hemispheres, were assessed for histological features associated with immunisation-mediated plaque removal, as previously defined: residual plaque cores in plaque-free areas, moth-eaten appearance of remaining plaques, phagocytosed Aβ within microglia, and marked cerebral arteriolar and capillary amyloid angiopathy (Nicoll *et al.*, 2006b). Plaque removal was scored semi-quantitatively as: very extensive (i.e. nearly complete clearance of plaques, +++), intermediate (i.e. multiple and/or extensive plaque-free foci each involving a >1 cm length of cortical ribbon, ++), very limited (i.e. single and/or small plaque-free foci each involving a <1 cm length of cortical ribbon, +) or no evidence of plaque removal (-).

*Method 2.* Large coronal paraffin sections of a single cerebral hemisphere from each case were immunolabelled for Aβ were digitally scanned, the cortex was overlaid with 4-mm2 squares tiled contiguously such that the entire neocortical ribbon was sampled, and each box was scored for plaques in a manner adapted from the Consortium to Establish a Registry for Alzheimer's disease protocol (frequent = 3, moderate = 2, sparse = 1, none = 0) (Mirra *et al.*, 1991). The results were expressed as A plaque score, indicating the mean of the score in all boxes per subject, and as the percentage of boxes for each category represented graphically by a colour code (frequent = red, moderate = yellow, sparse = green, none = blue).

Cerebrovascular territories (anterior, middle and posterior cerebral arteries) (Kalaria *et al.*, 2015) were delineated on the scanned images. Watershed zones, defined as 20 squares each of 4 mm2 spanning the arterial territory boundaries, were compared with the remaining squares remote from the watershed zones.

Peak anti-AN1792 antibody titres were obtained from the original study data provided by Elan Pharmaceuticals (Bayer *et al.*, 2005). Mean titres were calculated, defined as total serum anti-AN1792 antibody titre in ELISA units over the period of treatment for each participant divided by the number of assays for that individual (Bayer *et al.*, 2005; Holmes *et al.*, 2008).

**Tau assessment**

In neuropathologically confirmed Alzheimer’s cases, areas of neocortex were classified as either containing Aβ plaques (designated Aβ+) or lacking Aβ plaques (designated Aβ-), corresponding to the areas from which plaques had been extensively removed (method 1). Corresponding areas of neocortex were identified in parallel sections immunolabelled for tau, images were captured from 10 microscope fields (x20 objective) and assessed for: tau-immunoreactive neuronal cell bodies (expressed as number/10 fields); dystrophic neurite clusters (expressed as number/10 fields) and neuropil thread density (designated sparse, moderate or frequent and expressed/field (Alafuzoff *et al.*, 2008).

**Statistical analysis**

Assessment of normality of the variables A plaque score, mean and peak anti-AN1792 antibody response, and each tau feature was determined by examination of quantile-quantile plots. The relationship of A plaque score to the immune response (mean and peak anti-AN1792 antibody titres) was investigated by non-parametric Spearman rank correlation. To assess whether the survival time related to the extent of plaque removal, a parametric independent samples t-test was used to compare survival in the five subjects with the most extensive plaque clearance with that in the remaining Alzheimer’s subjects. To explore the effect of A plaque removal on tau pathology, the number of tangles and dystrophic neurites, and the neuropil thread density were compared between regions with or without A plaques, by non-parametric Mann-Whitney U-test. Continuously distributed data are displayed using box-and-whisker plots; while the scoring expressed as percentage is illustrated using pie chart. To assess whether A plaque score was linked to the vascular supply, one-way ANOVA was performed to assess difference between the cerebrovascular regions, and independent samples t-test between the watershed and non-watershed areas. SPSS software (version 24) was used for all analyses and p values less than 0.05 were considered statistically significant throughout.

**Data availability**

The data used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Results**

**Clinical details of participants**

Clinical details of AN1792 trial participants included in the *post-mortem* neuropathological follow-up study are shown in Table 1. The duration of dementia from time of diagnosis to death ranged from 6-19 years. All patients had a clinical diagnosis of probable mild to moderate Alzheimer’s disease (14–26/30 points on the MMSE) (Bayer *et al.*, 2005; Holmes *et al.*, 2008). Overall, 19/22 participants had received the active agent (AN1792) and three the adjuvant alone as a placebo. Fourteen of the 19 patients (74%) had developed detectable antibodies to AN1792 in peripheral blood. Survival times after the first immunisation varied widely, from 4 to 184 months. The clinical side-effect associated with Aimmunotherapy with AN1792, termed “meningoencephalitis” (Orgogozo *et al.*, 2003), was observed in only one of the 22 patients (case 1) (Nicoll *et al.*, 2003) (Table 2). *APOE* genotypes were typical of a population with dementia: 11/14 Alzheimer’s cases and one of the four non-Alzheimer’s cases with known *APOE* genotypes were *APOE* ε4 carriers.

**Neuropathological diagnoses**

The neuropathological analyses are shown in Table 2. Seventeen of the 22 cases (77%) had a distribution of tangles and at least some residual Aβ pathology indicating the cause of dementia had been Alzheimer’s disease (Table 2a), of which 16 were Braak tangle stage V/VI (B3) and one case, a patient who had died just 4 months after the first immunisation, was Braak stage III/IV (B2). Of the 17 neuropathologically confirmed Alzheimer’s cases, 16 had received the active agent and one the placebo. Of the five non-Alzheimer’s cases, three had received the active agent and two the placebo. Five of the 22 participants (23%) had non-Alzheimer’s causes for dementia: progressive supranuclear palsy (n=1), Lewy body disease (n=1), vascular brain injury (n=1) and frontotemporal lobar degeneration (FTLD-TDP43, n=2) (Table 2b).

**Evidence of plaque clearance**

*Method 1.* Aβ-immunolabelled sections from all cerebral cortical regions sampled were assessed for the specific histological features we previously associated with immunisation-mediated plaque removal in Alzheimer’s disease (Table 2) (Nicoll *et al.*, 2006b; Holmes *et al.*, 2008). These morphological markers of plaque clearance, also validated by their occurrence in PDAPP transgenic mice immunised with AN1792 (Schenk *et al.*, 1999; Schroeter *et al.*, 2008), include plaque-free areas, sometimes with residual plaque cores, a moth-eaten appearance of remaining plaques, phagocytosed Aβ within microglia, and marked cerebral arteriolar and capillary amyloid angiopathy (Nicoll *et al.*, 2006a), and are illustrated in Figure 1. As expected, the single placebo case with neuropathologically confirmed Alzheimer’ disease (case 15) had no evidence of plaque removal. In contrast, 14/16 (88%) of the neuropathologically confirmed Alzheimer’s patients who had received the active vaccine had evidence of plaque removal: five had nearly complete plaque removal with only scattered small patches containing residual plaques, four had intermediate plaque removal (i.e. multiple and/or extensive plaque-free foci each involving a >1 cm length of cortical ribbon), five had very limited plaque removal (i.e. single and/or small plaque-free foci each involving a <1 cm length of cortical ribbon), whereas only two had no evidence of plaque removal.

*Method 2.* Quantification of Aβ plaques in coronal hemisphere sections (Figure 2) showed that, in contrast to the single Alzheimer’s placebo case (Figure 2A), the five cases assessed by method 1 as having nearly complete removal of plaques all had >75% of the cortex scoring in the none/sparse plaque category (Figure 2B). In contrast, the two immunised Alzheimer’s cases with no histological features of plaque removal (Figure 2E) had >85% of the cortex containing moderate/frequent plaques. As expected, the plaque scores for the cases with neuropathologically diagnosed causes of dementia other than Alzheimer’s disease were predominantly none/sparse (Figure 1F).

Among the immunised Alzheimer’s cases, no differences were observed for the A plaque scores between the cerebrovascular territories (mean- anterior 1.59; middle 1.33; posterior 1.16 cerebral artery territories; *p*=0.485) or between the watershed compared to the non-watershed areas (mean watershed 1.37 *vs*. non-watershed 1.46; *p*=0.793).

**Time course**

Near-complete plaque removal was identified in the brains of two patients who died 14 years after immunisation (cases 20 and 21, 166 months and 173 months, respectively). Foci of plaque removal were present after as little as 4 months (case 2). These findings indicate that plaque removal can occur rapidly and be sustained for many years after active Aβ immunisation. The five patients with the most extensive plaque clearance had a mean survival of 115 months compared with 82 months for the remaining patients with Alzheimer’s disease (89 months excluding the participant who died from rupture of an abdominal aortic aneurysm 4 months after their first immunisation). However, there was no significant relationship between the extent of plaque removal and survival time since first immunisation dose (*r* = 0.182, *p* = 0.485), suggesting that extensive plaque removal does not confer survival benefit and that a prolonged time interval does not diminish the effect of the immunisation. Interpretation of this analysis is hampered by the small numbers of subjects, wide age range of subjects at recruitment, and the fact that the cause of death of some subjects was due to co-incident disease rather than dementia (Table 1).

**Aβ plaque scores and serum** **anti-AN1792 antibody titres**

Peripheral blood anti-AN1792 antibody titres available from the period of the trial (2000 - 2002) were analysed in relation to the Aβ plaque scores on *post-mortem* neuropathology (Table 2). In the neuropathologically confirmed Alzheimer’s cases, Aβ plaque scores showed a significant inverse correlation with both mean and peak anti-AN1792 antibody titres (*=*-0.664, p=0.005; *=*-0.617, p=0.011, respectively) (Figure 3), despite the interval of several years in most cases between the antibody assays and the *post-mortem* assessments. Aβ removal seemed to be most pronounced in the subjects who generated a substantial immune response to the vaccine, supporting the hypothesis that the anti-Aβ antibodies that are instrumental in removing the Aβ plaques from the brain.

**Tau**

To determine the local effect on tau of removing Aβ from the cortex, we compared tau pathology between neocortical areas with remaining Aβ plaques (Aβ+) and those without remaining Aβ plaques (Aβ-) (Figure 4). Tau-containing dystrophic neurite clusters and tau-containing neuronal cell bodies were significantly fewer in plaque-free regions (*p*=0.001), consistent with a local relative reduction in tau associated with Aβ immunisation-induced removal of plaques. Nevertheless, 15/16 of the immunised Alzheimer’s subjects had progressed to Braak stage V/VI (Table 2) which reflects widespread anatomical distribution of aggregated tau within the brain, suggesting that spread of tau pathology continued despite the removal of plaques. The single immunised Alzheimer’s subject not reaching this advanced stage of tau distribution had died shortly after his first immunisation dose at a relatively early stage of the disease (case 2, Braak stage III/IV, 4 months). Of note, all five cases with nearly complete removal of plaques had an advanced stage of tangle distribution within the cerebrum (Braak stage V/VI).

**Meningoencephalitis**

Only one of the 22 patients (case 1) was recognised to have had a clinical event corresponding to the post-immunisation meningoencephalitis described in a subsequent multinational phase 2a trial of AN1792 (Orgogozo *et al.*, 2003). As part of a trial extension phase she had a fifth injection, with a reformulated preparation containing polysorbate-80 as used in the subsequent trial, and six weeks later she became unwell with dizzy spells, drowsiness, an unstable gait and fever. Brain imaging showed extensive alterations in the cerebral white matter bilaterally and enhancement on the brain surface. Although, the post mortem analysis followed 11 months after the clinical episode, the neuropathological findings were striking with abundant leptomeningeal T lymphocytes, relatively scanty lymphocytes in the cerebral cortex, cortical microvascular lesions related to severe cerebral amyloid angiopathy, and oedema of the white matter ((Nicoll *et al.*, 2003), illustrated in Figure 5). Of note, 13/14 subjects with neuropathologically confirmed Alzheimer’s disease and histological evidence of plaque removal did not have such a clinical event and lacked a significant infiltrate of lymphocytes. Previous quantification showed in the meningoencephalitis case (case 1), the presence of 1024.5 CD3+ T lymphocytes/100 fields in the leptomeninges and 65.5 in the grey matter compared with median values of 12 in leptomeninges and 1.8 in the grey matter in immunised Alzheimer cases without encephalitis and 14.2 in leptomeninges and 7.3 in the grey matter in non-immunised Alzheimer’s disease cases (Zotova *et al.*, 2013). This absence of a significant lymphocytic infiltrate in all but one of the AN1792-treated patients is consistent with the plaque removal activity following AN1792 immunisation being primarily related to a humoural immune response.

**Cognitive function and cause of death**

Although at the time of entry to the trial all participants satisfied the criteria for mild/moderate dementia, 19/22 were assessed as having severe dementia prior to death (Table 1), notably including all five patients with near complete clearance of plaques from the brain (cases 7, 8, 16, 20 and 21). The late assessments were performed within a year of death so represent a good indication of the cognitive status in relation to the neuropathological findings. The remaining three participants had moderate dementia (cases 2, 10 and 11), had a neuropathological diagnosis of Alzheimer’s disease and had received the active agent. One showed intermediate plaque removal, the other two had evidence of only very limited plaque clearance. One of these three participants had died from rupture of an abdominal aortic aneurysm just 4 months after first immunisation. The other two died from bronchopneumonia, with dementia cited in the cause of death. A neurocognitive disorder was mentioned in the cause of death as stated on the death certificates for 19/22 participants. No patient died from a cause attributable to the immunisation.

**Non-Alzheimer’s cases**

Five of the 22 subjects (23%) had non-Alzheimer’s causes for dementia (Table 2b). Consistent with their non-Alzheimer’s diagnoses, they predominantly had low plaque scores (Figure 2F). Three of the non-Alzheimer’s subjects had received the active vaccine, only one of whom had evidence of circulating antibodies against AN1792 (case 12).

**Discussion**

Systematic *post-mortem* follow-up over a 15-year period of patients who had been enrolled in the first trial of Aβ immunisation in Alzheimer’s disease has yielded unique insights into the effects of Aβ removal and the progression of disease. Such a long-term neuropathological analysis of a therapeutic trial for a neurological condition, in this case with a >25% *post-mortem* rate, has rarely, if ever, been performed previously. The study has limitations, including the single time-point of analysis for each subject inevitable in a *post-mortem* study, in contrast with serial assessment of amyloid load now possible with *in vivo* PET imaging (Liu *et al.*, 2015). However, we were able to ascertain the long-term effects of active Aβ immunisation on plaque clearance, analyse variation between cases, study the patchy nature of plaque removal, and exploit this patchy removal, by comparing areas with plaques removed to areas with plaques remaining in the same brains to act as internal controls, to study its effect on tau pathology. Therefore, the lack of significant numbers of placebo subjects coming to *post-mortem* neuropathological examination did not compromise these aims.

Here we report an important finding of the long-term effects of active A immunisation in not only removing plaques but keeping plaques at bay for up to 14 years, with the brains of some subjects rendered virtually plaque-free for many years after the therapeutic intervention had ceased. There are no published data comparable to this. Most clinical trials of A immunotherapy for Alzheimer’s disease subsequent to AN1792 have employed passive immunisation strategies (Selkoe and Hardy, 2016). A particular advantage of active immunisation, stimulating the host’s own immune system to produce the antibodies, over passive Aβ immunisation in which exogenous antibodies are provided, is the prolonged effect achievable even in an elderly population, as demonstrated here. The importance of this observation is that if Aβ immunotherapy should prove successful in preventing Alzheimer’ disease, rather than treating established disease, then early active immunisation would be an effective strategy, as we show here the level of the immune response is sufficient to stimulate and maintain the A clearance over many years. Clinical trials of passive Aβ immunotherapy are currently in progress in groups at high risk of developing Alzheimer’s disease, including those with a familial autosomal dominant form of the disease due to presenilin 1 mutation or *APOE* ε4 homozygotes (Prevention and Generation studies) (The Lancet, 2012; Aging, 2016). Whilst these are very important studies as a test of principle, widespread use in the population of passive immunotherapy over a period of many years or decades would probably be impracticable. In contrast, active immunisation, analogous to immunisation for the prevention of bacterial and viral infections, seems more feasible.

Another notable finding in this study is the *post-mortem* neuropathological observation that 5/22 participants (23%) had causes for their dementia other than Alzheimer’s disease. Trials without neuropathological follow-up lack definite knowledge of the diagnostic error, and inaccuracy of the clinical diagnosis of Alzheimer’s disease has hampered the early immunotherapy trials. For example, consistent with our finding, *post-hoc* analysis of a trial of the anti-Aβ antibody bapineuzumab showed that up to a third of subjects lacked amyloid on imaging, so probably did not have Alzheimer’s disease (Liu *et al.*, 2015). Clearly, the statistical power of trials of therapy for Alzheimer’s disease is severely compromised if a substantial proportion of the patients do not have the disease at which the potential therapy is targeted. More recent developments in trial design require at subject enrolment that brain amyloid is detected by PET scans and cerebrospinal fluid analysis of Aβ and tau is consistent with Alzheimer’s disease. Both forms of assessment can be expected to have improved the accuracy of diagnosis in more recent trials (Selkoe and Hardy, 2016).

Most of the patients in our study showed a decline in cognitive function from mild/moderate dementia at trial entry to severe dementia prior to death. Of particular note, five patients with neuropathological confirmation of Alzheimer’s disease who had received the active vaccine, developed circulating anti-AN1792 antibodies and had nearly complete clearance of plaques, all progressed to severe dementia. Soluble/oligomeric A also appeared to have been cleared in one such case previously examined (Maarouf *et al.*, 2010). This finding supports and strengthens our previous conclusion at 6 years of follow-up, although based at that stage on only two of the patients, that removing the plaques in established Alzheimer’s disease fails to halt the cognitive decline (Holmes *et al.*, 2008). This conclusion implies that in established Alzheimer’s disease, pathological components other than Aβ plaques – such as microglial activation and/or tau accumulation – predominate in perpetuating the progression of dementia.

Since the first Aβ immunotherapy trial (AN1792), the neuropathological follow-up of which is presented here, the landscape has changed considerably, with huge financial investment by the pharmaceutical industry and many thousands of patients with dementia exposed to various active and passive Aβ immunotherapies (Selkoe and Hardy, 2016). Studies to date have shown no or limited evidence of benefit to cognitive function. However, according to amyloid scan data, most trials have shown only modest effects on reducing amyloid plaque burden (Rinne *et al.*, 2010; Salloway *et al.*, 2014), contrasting with our neuropathological findings here relating to AN1792. A notable exception is the monoclonal antibody aducanumab (Sevigny *et al.*, 2016) of which a relatively small clinical trial of patients with a clinical diagnosis of prodromal or mild AD and visually positive Aβ PET scan employing very high doses of antibody, yielded imaging evidence of very extensive amyloid clearance, comparable to that identified histologically in the current study. Stabilisation of cognitive decline was demonstrated in this preliminary clinical trial with aducanumab in patients with evidence of amyloid removal on PET imaging.

Fourteen of the 16 (88%) Alzheimer’s patients receiving the active agent in this study had evidence of plaque removal, but with considerable variability from case to case and striking patchiness of plaque removal in some cases. This is in contrast to the relatively uniform distribution of plaques throughout the cerebral neocortex typically seen in untreated Alzheimer’s disease. Similar patchiness of Aβ removal has been demonstrated with amyloid PET scans before and after treatment of patients in trials of subsequent immunotherapy agents (e.g. Bapineuzumab) (Liu *et al.*, 2015). The National Institute on Aging-Alzheimer’s Association guidelines for neuropathological assessment of Alzheimer’s disease have been applied in this study to provide a standardised comparator with non-immunised Alzheimer’s cases (ABC, Table 2). This system is based on the progressive accumulation and anatomical progression of Alzheimer’s pathology which occurs during the natural history of the disease in the form of A (A) and tau (B) and maximal focal density of neuritic plaques (C). This progressive accumulation of neuropathological features has been disrupted as a consequence of the Aβ immunisation, and thus the ABC assessments under-represent the profound alterations in A and tau pathology which are better reflected by the quantitative analyses shown. For example, cases 7 and 8 had very low levels of plaque Aβ, in the cerebral cortex only, with none in the basal ganglia, brainstem or cerebellum (hence A1, as shown in table 2), despite the advanced stage of distribution of tangles (B3, i.e. Braak V/VI), an overall pattern consistent with Alzheimer’s pathology in which most of the Aβ has been removed by the immunotherapy.

There are two likely mechanisms of removal of Aβ following immunisation, with entry of antibodies into the brain and binding of anti-Aβ antibodies to plaques (Boche *et al.*, 2010a). Firstly, opsonisation as a consequence of antibody binding provokes microglia to phagocytose Aβ by binding of the IgG Fc region to Fc receptors on the microglial cell surface. Evidence for the occurrence of this mechanism in relation to AN1792-mediated plaque removal comes from the presence of Aβ within the cytoplasm of microglia as we have previously demonstrated by double label confocal microscopy (Nicoll *et al.*, 2006a; Boche *et al.*, 2010a) giving a characteristic appearance of small dense clusters of Aβ immunoreactivity, often amongst “moth-eaten” or disrupted plaques as illustrated in Figure 1c. This appears to be followed, once plaques have been removed from a region of cortex, by subsequent dispersal (Zotova *et al.*, 2011) and down-regulation of microglia (Zotova *et al.*, 2013). The second mechanism of plaque removal appears to involve solubilisation of Aβ, with high levels of soluble Aβ detected in some immunised cases (Maarouf *et al.*, 2010). Solubilisation seems to result in translocation of Aβ to the walls of arteries and capillaries resulting in an increased severity of cerebral amyloid angiopathy (Boche *et al.*, 2008; Sakai *et al.*, 2014), a feature which may be localised and transient. Although cerebral amyloid angiopathy cannot yet be readily imaged *in vivo* in the human brain, evidence suggests that it is a major contributor to the complication of Amyloid–Related Imaging Abnormalities (ARIA) hampering more recent and current clinical trials, including those of passive immunotherapy (Sperling *et al.*, 2011; Sevigny *et al.*, 2016) as discussed below.

Only one of the 22 patients (case 1) in our study of the phase 1 trial of AN1792 was observed to have the side effect termed “meningoencephalitis” described in the subsequent phase 2a trial (Orgogozo *et al.*, 2003) which halted further development with AN1792 (Vellas *et al.*, 2009). Interestingly, the complication in case 1 developed only during a trial extension phase shortly after the patient had a fifth injection, with a reformulated preparation containing the solubilising agent polysorbate-80 as used in the subsequent phase 2a trial. There is little information on the pathological substrate of this complication, limited to two patients who received AN1792, including the initial description of case 1 in this present study (Nicoll *et al.*, 2003) and one subsequent case from the phase 2a trial (Ferrer *et al.*, 2004). However, the pathology shares features with sporadic Aβ-related angiitis, in which histological evidence has been observed of a T lymphocyte immune response to Aβ in the cerebral vasculature and also, in some cases, in the parenchyma (Scolding *et al.*, 2005). We previously suggested that the complications experienced with AN1792 were a consequence of solubilisation of plaques with translocation of Aβ to the vasculature, increasing the severity of cerebral amyloid angiopathy and consequently generating microhaemorrhages and white matter oedema (Boche *et al.*, 2008; Boche *et al.*, 2010a). It was unclear whether or not a lymphocytic reaction was essential to the development of this complication and we predicted that it may be encountered in any therapy designed to remove Aβ from the brain. Indeed, a recurring side effect in Aβ immunotherapy trials subsequent to AN1792 has been the so-called “Amyloid–Related Imaging Abnormalities” (ARIA) (Sperling *et al.*, 2011), mainly in the form of focal white matter oedema and cortical microhaemorrhages, occurring in up to half of treated patients (Sevigny *et al.*, 2016) and limiting antibody dosage (Sperling *et al.*, 2011). ARIA is identified on MRI scans and is usually, but not always, asymptomatic. In retrospect, the imaging features of the meningoencephalitis experienced with AN1792 are similar to ARIA, however unfortunately pathological information on ARIA, for comparison with the findings from AN1792, is lacking.

Cerebrospinal fluid and blood samples from these patients were not available to permit assessment of a time period of plaque-binding antibodies following immunisation. However, anti-AN1792 antibodies were assayed in a subgroup of participants in a previous study (Holmes *et al.*, 2008) at a time point 6 years after immunisation with AN1792 and showed persistence of circulating anti- AN1792 antibodies at that stage. We explored the presence of antibodies on remaining plaques previously when we had 11/16 of the immunised Alzheimer cases presented in the current study (Zotova *et al.*, 2013). We found IgG to be variably present on plaques both in immunised and non-immunised Alzheimer’s disease cases, with no consistent pattern. We were not able to distinguish between plaque-bound antibodies specifically directed against Aβ, whether generated in response to the AN1792 active vaccine or not, from antibodies bound to other plaque components due to technological limitations. However, demonstration of IgG bound to plaques does confirm the ability of IgG to cross the blood brain barrier. As evidence suggests that plaque removal requires access of antibodies from the bloodstream into the brain parenchyma, this raises the possibility that vascular factors are a determinant in the success of plaque removal. We explored whether the patchiness of plaque removal could reflect anatomical cerebral arterial territories or arterial watershed regions but found that the cerebrovascular anatomy did not explain the heterogeneity in plaque removal. This patchiness of removal has been a recurring phenomenon in subsequent A immunotherapy trials (Sperling *et al.*, 2012; Sevigny *et al.*, 2016) and remains unexplained, but could perhaps be due to local alterations in the blood-brain barrier associated with an ageing cerebral vasculature, damage to pericytes (Sagare *et al.*, 2013; Miners *et al.*, 2018), or specific features of Alzheimer’s pathology such as cerebral amyloid angiopathy (Skrobot *et al.*, 2016).

We took advantage of this patchy nature of plaque removal to investigate the effects on tau, comparing regions of cortex from which plaques had been removed with immediately adjacent regions where plaques remained. Our findings demonstrate that plaque removal mediated by active Aβ immunisation can influence tau accumulation for up to 14 years, reducing local accumulation of tangles and dystrophic neurites within the cerebral cortex. This implies that late in the disease, in the absence of immunotherapy, Aβ continues to drive local accumulation of tau.

The reduction in tau-containing plaque-associated dystrophic neurites is a striking consequence of immunisation-mediated removal of Aβ from the cortex and has been described previously (Nicoll *et al.*, 2003; Ferrer *et al.*, 2004; Boche *et al.*, 2010b). The mechanism for this localised reduction in tau is unclear, but it could conceivably reflect, firstly, restored neuronal homeostasis leading to dismantling of the aggregated tau within the neuronal processes. Previous studies have identified a reduction in neuritic curvature which would be consistent with “straightening” of abnormal neurites after Aβ removal (Serrano-Pozo *et al.*, 2010; Paquet *et al.*, 2015) and observation after immunisation of a reduction in tau kinases responsible for phosphorylating tau, would support this possibility (Ferrer *et al.*, 2004; Amin *et al.*, 2015). No extra-neuronal tau was identified and residual tau-negative dystrophic neurites were not identified. Further support for improved “neuronal health” after removal of Aβ would include down-regulated apoptosis and autophagy (Paquet *et al.*, 2018). In addition, a reduction of local synaptic abnormalities was suggested by one case study (Ferrer *et al.*, 2004); however, overall cortical synaptic status assessed by synaptophysin immunohistochemistry did not support this finding (Boche *et al.*, 2010a). A second possible explanation for the reduction in tau-containing dystrophic neurites is the removal of the dystrophic neurites by microglial phagocytosis. Identification of a reduced neuropil density after immunisation could support this mechanism (Paquet *et al.*, 2015); however, phagocytosed tau, unlike Aβ, was not detected in microglia in areas of cortex cleared of plaques making this latter possibility less likely. It is notable that all components of the plaque appear to be dis-assembled following removal of Aβ by immunotherapy, including: tau within the dystrophic neurites, the dystrophic neurites themselves, and also microglia (Zotova *et al.*, 2011), astrocytes and apoE associated with plaques (Nicoll *et al.*, 2006a). The neuritic plaque is the single point at which many of the key features of AD pathophysiology converge: Aβ, tau, microglia and apoE and therefore it seems likely to represent a key component of the evolution of the disease process.

 Nevertheless, we found that all patients had progressed to Braak stage V/VI, which represents an advanced spread of tangle pathology throughout the brain. Tau has been proposed to spread through the brain from neuron to neuron by a “prion-like” mechanism (Clavaguera *et al.*, 2009; Spillantini and Goedert, 2013). Our observations suggest that removal of plaque-associated Aβ after the initiation of tau accumulation may not prevent the continued spread of tau pathology, a contention supported by our previous observations when compared to a non–immunised Alzheimer’s cohort (Boche *et al.*, 2010b). This finding is relevant to the lack of observed benefit to cognitive function in our study and subsequent phase III trials of Aβ immunotherapy in established Alzheimer’s disease, as cognitive dysfunction is known to correlate more closely with accumulation of tau than that of Aβ (Minett *et al.*, 2016). Tau ligands for PET imaging are becoming available and may in future provide further information on the persistence or progression of tau pathology after Aβ immunotherapy. There is growing interest in use of Aβ immunotherapy early in the course of the Alzheimer’s process, for example at the stage of mild cognitive impairment, or even as a preventative measure (The Lancet, 2012). Our findings in this study in relation to tau suggest that very early intervention, before significant self-propagating accumulation of tau, is desirable to prevent progression. The outcome of such preventative studies, the ultimate test for the amyloid cascade hypothesis, is eagerly awaited.

Aβ immunotherapy trials subsequent to AN1792 have represented a huge financial investment amounting to many hundreds of millions of dollars and it is disappointing that no systematic *post-mortem* neuropathology follow-up seems to have been organised for those trials to help to understand the reasons for the limited clinical benefit and to inform future research studies. Even though the trials of Aβ immunisation have so far failed to meet their primary cognitive endpoints, analysis of the varying neuropathological effects of targeting different specific forms of Aβ, such as oligomeric and fibrillary forms, could provide important information on key correlates between Alzheimer pathophysiology, the immune response and cognitive function which are as yet poorly understood.

**Acknowledgments**

We are grateful to all patients and carers who took part in the study. We thank Elan Pharmaceuticals for access to phase I AN1792 treatment study data and AN1792 antibodies, with special thanks to Dora Games and Peter Seubert; J Gifford, Helen Cartwright, Carol Hall and other clinical research staff at Southampton, Cardiff, Swindon, Bath and Bristol; staff of the neuropathology laboratory, including Sammy Reynolds, Histochemistry Research Unit and Biomedical Imaging Unit at Southampton General Hospital; Prof Margaret Esiri and Dr Catherine Joachim at the University of Oxford.

**Funding**

Alzheimer’s Research UK (ART/PG2006/4, ART-EXT2010-1, ARUK-EG2015A-4) and the Medical Research Council (G0501033) funded this study.

**References**

Aging NIo. People at genetic risk for Alzheimer's disease to test prevention drugs 2016 [cited; <https://www.nia.nih.gov/news/people-genetic-risk-alzheimers-disease-test-prevention-drugs> ].

Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H*, et al.* Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008; 18(4): 484-96.

Amin J, Paquet C, Baker A, Asuni AA, Love S, Holmes C*, et al.* Effect of amyloid-beta (Abeta) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3beta. Neuropathol Appl Neurobiol 2015; 41(4): 445-57.

Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L*, et al.* Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64(1): 94-101.

Boche D, Denham N, Holmes C, Nicoll JA. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 2010a; 120(3): 369-84.

Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C*, et al.* Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 2010b; 120(1): 13-20.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM*, et al.* Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008; 131(Pt 12): 3299-310.

Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A*, et al.* Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11(7): 909-13.

Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14(1): 11-20.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A*, et al.* Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372(9634): 216-23.

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC*, et al.* National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8(1): 1-13.

Kalaria R, Ferrer I, Love S. Vascular disease, hypoxia, and related conditions. In: Love S, Budka H, Ironside JW, Perry A, editors. Greenfield's Neuropathology. New-York: CRC Press Taylor & Francis Group; 2015. p. 148-9.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS*, et al.* Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 2015; 85(8): 692-700.

Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC*, et al.* The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 2010; 5: 39.

Miners JS, Schulz I, Love S. Differing associations between Abeta accumulation, hypoperfusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease. J Cereb Blood Flow Metab 2018; 38(1): 103-15.

Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C*, et al.* Microglial immunophenotype in dementia with Alzheimer's pathology. J Neuroinflam 2016; 13(1): 135-45.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM*, et al.* The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41(4): 479-86.

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW*, et al.* National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123(1): 1-11.

Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J*, et al.* Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408(6815): 982-5.

Nicoll J, Barton E, Boche D, Neal J, Ferrer I, Thompson P*, et al.* A beta species removal after A beta(42) immunization. Journal of Neuropathology and Experimental Neurology 2006a; 65(11): 1040-8.

Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P*, et al.* Abeta Species Removal After Abeta42 Immunization. J Neuropathol Exp Neurol 2006b; 65(11): 1040-8.

Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9(4): 448-52.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC*, et al.* Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61(1): 46-54.

Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F*, et al.* Effect of active Abeta immunotherapy on neurons in human Alzheimer's disease. J Pathol 2015; 235(5): 721-30.

Paquet C, Nicoll JA, Love S, Mouton-Liger F, Holmes C, Hugon J*, et al.* Downregulated apoptosis and autophagy after anti-Abeta immunotherapy in Alzheimer's disease. Brain Pathol 2018; 28(5): 603-10.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE*, et al.* 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9(4): 363-72.

Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A*, et al.* Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nature communications 2013; 4: 2932.

Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S*, et al.* Abeta immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol 2014.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M*, et al.* Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370(4): 322-33.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T*, et al.* Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740): 173-7.

Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T*, et al.* Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008; 28(27): 6787-93.

Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J*, et al.* Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128(Pt 3): 500-15.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine 2016; 8(6): 595-608.

Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA*, et al.* Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010; 133(Pt 5): 1312-27.

Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M*, et al.* The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 2016; 537(7618): 50-6.

Skrobot OA, Attems J, Esiri M, Hortobagyi T, Ironside JW, Kalaria RN*, et al.* Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain 2016; 139(11): 2957-69.

Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC*, et al.* Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11(3): 241-9.

Sperling RA, Jack CR, Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT*, et al.* Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7(4): 367-85.

Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12(6): 609-22.

The Lancet N. Colombia at the centre of preclinical AD research. The Lancet Neurology 2012; 11(7): 567.

Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G*, et al.* Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6(2): 144-51.

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S*, et al.* Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain 2013; 136(Pt 9): 2677-96.

Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D. Microglial alterations in human Alzheimer's disease following Abeta42 immunization. Neuropathol Appl Neurobiol 2011; 37(5): 513-24.

**Legends**

**Figure 1.** Illustrations of the morphological features of amyloid-β immunohistochemistry associated with plaque clearance. (A) Plaque-free areas of cerebral cortex containing scattered “naked” residual plaque cores, lacking surrounding diffuse amyloid-β. (B) A “moth-eaten” appearance of some remaining plaques. (C) A granular pattern of intracytoplasmic Aβ within microglia (arrows) with some “moth-eaten” extracellular amyloid-β (right of image). (D) Triple label confocal image demonstrating microglia clustered around a remaining plaque (A, cyan; HLA-DR, green; CD68, red; overlap, yellow). (E) A small cortical area lacking plaques, with remaining plaques on either side, associated with full-thickness, full-circumference amyloid-β staining of overlying leptomeningeal arteries indicating severe cerebral amyloid angiopathy. (F) Numerous capillaries with amyloid-β staining, indicating capillary angiopathy, in a plaque-free area of cerebral cortex. Figures A-C, E and F: immunohistochemistry for pan-Aβ. Figure: D triple label confocal microscopy for amyloid-β, HLA-DR and CD68. Scale bar A, B, C and F = 100m; D = 50m; E = 1mm.

**Figure 2.** Scans of coronal histological sections of cerebral hemisphere from participants in the AN1792 trial immunolabelled to demonstrate Aappearing black). The cases are grouped according to the extent of positive histological evidence of plaque removal on examination of all brain regions (method 1). (A) placebo with neuropathologically confirmed AD demonstrating a continuous band of plaques throughout the cerebral neocortex (case 15); (B) AD subjects with nearly complete plaque removal (cases 7, 8, 16, 20 and 21); (C) AD subjects with intermediate plaque removal (cases 1, 2, 6 and 9); (D) AD subjects with limited plaque removal (cases 4, 10, 11, 27 and 22); (E) AD subjects with no evidence of plaque removal (cases 3 and 19) and (F) non-AD subjects (cases 5, 12, 13, 14 and 18). A plaque density was scored throughout the neocortex of each hemisphere section using a CERAD-adapted method (method 2) with the results colour-coded for illustrative purposes as: frequent plaques=red, moderate=yellow, sparse=green, none=blue, expressed as % of each category.

**Figure 3.** Negative association between the mean anti-AN1792 antibody response during the trial period and po*st-mortem* A plaque score indicating that the magnitude of the immune response to AN1792 influenced the degree of A removal from the brain.

**Figure 4.** The effect of A removal was quantified for each of the different histological features of intraneuronal tau accumulation (tangles, dystrophic neurite clusters and neuropil threads) by comparing cortical regions with A plaques remaining (A+) to regions with A plaques removed (A-). There were significantly fewer tangles and dystrophic neurite clusters in the regions where A plaques had been removed in response to the Aimmunotherapy; not significant for neuropil threads. Scale bar = 50m

**Figure 5.** Illustrations of the single case of post-immunisation meningoencephalitis (case 1). Numerous lymphocytes in the subarachnoid space clustered around arteries showing the “double-barrel” morphology associated with severe cerebral amyloid angiopathy (A) haematoxylin & eosin and (B) CD3 immunohistochemistry for T lymphocytes. (C) Lymphocytes were relatively scanty in the cerebral cortex (CD3 immunohistochemistry). (D) Cerebral white matter showed focal rarefaction of myelinated fibres (Kluver Barrera). (E) Old cortical microbleed indicated by the presence of a cluster of haemosiderin pigment granules. (F) Severe cerebral amyloid angiopathy with full thickness, full circumference involvement of the walls of leptomeningeal and parenchymal arteries by amyloid-β (immunohistochemistry for pan-Aβ). Scale bar A and E = 100m; B and D = 50m; C = 30m; F = 500m.